Science 37, a company focused on “site-less” clinical trials, and VisualDx, a diagnostic clinical decision support system for physicians and front-line providers has announced a strategic partnership that will empower the public to make better informed decisions with their doctors about managing skin problems.
As part of this agreement, both Science 37 and VisualDx will look to engage patients and clinicians from their respective networks to boost clinical trials awareness, education, and participation. The synergies will come from combining VisualDx’s consumer reach and expert curated diagnostic database of over one hundred thousand skin-related images with Science 37’s patient-driven content and media production capabilities.
Both founded by dermatologists, Science 37 and VisualDx began with a focus on improving the diagnosis and treatment of skin conditions since 1 in 4 Americans are seen by a physician for a skin problem each year. At the same time, non-dermatologists misdiagnose skin conditions almost half the time.
The full VisualDx suite is a web and app-based clinical decision support system designed to enhance diagnostic accuracy, aid therapeutic decisions, and improve patient safety. Used in more than 1,700 hospitals and clinics around the world, VisualDx is based on the world’s largest curated and metadata-enabled medical image library. Its current consumer facing website, Skinsight (http://www.skinsight.com), and forthcoming CoreML enabled app Aysa (http://www.askaysa.com), attracts over half a million unique visits per month with trusted and unbiased skin health information.
Unlike other digital health solutions in the space, Science 37’s Metasite™ or “site-less” model helps researchers engage directly with trial participants from study start to finish. This direct connection improves the participant experience, increases diversity across trials, and accelerates study recruitment.
“Despite increased availability and improvements in public information and mobile technology, the barriers to accurate diagnosis and access to clinical trials remain too high,” said Art Papier, MD, CEO and co-founder of VisualDx. “Partnering with Science 37 brings incredible resources to our clinicians and patients, including matching patients to clinical trials they can participate in from the comfort of their home.”
